Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Antibiotics Summit 2019

Antibiotics Summit 2019

We invite all the participants from all over the world to attend ‘5th International Conference on Antibiotic & Antibiotics Resistance' to be held on May 30-31, 2019 at  Orlando, Florida, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Details of Antibiotics Resistance Conference in 2019 in USA:

ConferenceSeries.com organizing Antibiotics Resistance Conferences in 2019 in USA. We organize Antimicrobial Meetings in the fields related to Antibacterial Studies and Research.

Conference Name

Place

Date

Antibiotics Summit Conference 2019

 

Orlando, Florida, USA

May 30-31 , 2019
 


The use of antibiotics having an important concern for selection of resistance, not completely among pathogenic bacteria also among the commensal ones. In public health antimicrobial resistance is a major problem due to possibility in therapeutic failure. The primary objective of this meeting is to compile researchers involved in antibiotic resistance prevention and control. The meeting will take a unified approach to research and it will bring about researchers specializing in different subjects related to antibiotic resistance. We expected to present a universal vision of the importance of antimicrobial resistance in different ecosystems and what can be done about it.

Why to attend?

ANTIBIOTICS SUMMIT 2019 is a platform to discuss and learn about the latest advancements in the field of Antibiotics as the world’s consideration turned regarding the urgency of new antibiotics as the antimicrobial resistance is growing day by day. Many developed nations and International health organizations are trying to focus of the current situation and making new policies to prevent the adverse effects of Antibiotic resistance.

The 2-day conference gathers researchers, academia, labs, Drug Manufacturers, government agencies, health professionals, hospitals, young investigators, pharma and labs and presents their opinions through key notes, and case study presentations. This conference lays a platform for all the researchers working in the field of Antibiotics to know the latest developments and the current situation of the Antibiotic resistance problem.

Who Should Attend and Who You’ll Meet

5th International Conference on Antibiotic & Antibiotics Resistance is exclusively designed for:

  • Researchers

  • Academia

  • Drug Manufacturers

  • Government agencies

  • Healthcare professionals

  • Hospitals/ Clinics

  •  Methodologists

  • Young investigators

  • Medical Directors

  • Principal Investigators

  • Clinical Research organizations

  • Senior executives of Biotech, Biomedical, Medical devices and Pharmaceutical industries

This conference lays a platform for all the researchers working in the field of microbiology/ antibiotics to know the latest developments and the current situation of the Antibiotics and Antibiotics Resistance problem.

Sessions/Tracks

Track 1Origins and Types of Antibiotic and Antimicrobials

The world is in the midst of an emerging crisis of antibiotic resistance to microbial pathogens. Numerous pathogens that have become resistant to commonly used antibiotics have been described in various contexts, including drug-resistant methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pneumonia, and Mycobacterium tuberculosis. Considering the breadth of effect and significant impact on morbidity and mortality, multi-drug-resistant (MDR) pathogens are a substantial threat to public health. Although this problem calls for the development of new antibiotics with new mechanisms of action, the pharmaceutical industry has abandoned the sector as less lucrative for their investments. The number of new antibiotics approved by the U.S. Food and Drug Administration (FDA) declined dramatically during the past 2 decades.

Track 2: Evolution and Mechanisms of Antibiotics and Antimicrobials resistance

Increasing drug resistance is caused primarily by inappropriate use of antimicrobials in humans as well as in animals, and spread of resistant strains between the two. Antibiotics develop selective pressure in bacterial strength, resulting accessible bacteria to die; this enhances the percentage of resistant bacteria which continue increasing. With resistance to antibiotics becoming more common there is greater need for alternative treatments. New antibiotic therapies have been needed, but new drug development is becoming scarce.
A World Health Organization (WHO) report released April 2014 stated, "This serious threat is no longer a prediction for the future, it is happening right now in every region of the world and has the potential to affect anyone, of any age, in any country. Antibiotic resistance—when bacteria change so antibiotics no longer work in people who need them to treat infections—is now a major threat to public health. Increasing public calls for global collective action to address the threat include proposals for international treaties on antimicrobial resistance.

Track 3: Genetics and Proteomics of antimicrobial resistance

Bacteria can acquire antibiotic resistance genes from other bacteria in several ways. By undergoing a simple mating process called "conjugation," bacteria can transfer genetic material, including genes encoding resistance to antibiotics (found on plasmids and transposons) from one bacterium to another. Antibiotic resistance genes have been identified in diverse environments including soil, gull feces and, increasingly, in the human gut microbiota. Scientists have applied a range of approaches to detect antibiotic resistance genes in environmental or non-clinical microbiomes, all of which have their own inherent strengths/limitations.
Proteomic studies have improved our understanding of the microbial world. The most recent advances in this field have helped us to explore aspects beyond genomics. Proteomics has also advanced our knowledge of mechanisms of bacterial virulence and some important aspects of how bacteria interact with human cells and, thus, of the pathogenesis of infectious diseases. We have used proteomic technology to elucidate the complex cellular responses of Bacillus subtilis to antimicrobial compounds belonging to classical and emerging antibiotic classes.

Track 4: Antimicrobial resistance and its emergence

The use of antimicrobials in animals closely parallels their discovery and usage in humans.  Sulfonamide was the first antimicrobial to be introduced to food animal medicine in the 1940s. Antimicrobial resistance emerges from the use of antimicrobials in animals and the subsequent transfer of resistance genes and bacteria among animals and animal products and the environment.  Antibiotics are also given to food animals for growth promotion and prophylactic medication. In 2011, a total of 13.6 million kilograms of antimicrobials were sold for use in food-producing animals in the United States, which represents 80% of all antibiotics sold or distributed in the United States. Of the antibiotics given to animals from 2009 through 2013, just above 60% distributed for food animal use are "medically-important" drugs, that are also used in humans. The rest are drug classes like ionophores which are not used in human medicine. here are also global concerns over the use of antibiotics for growth promotion or therapy purposes because of the potential for some drugs to enter the human food chain despite rigorous withdrawal measures and testing to prevent antibiotic residues in food, increasing antibiotic resistance in animals, a potential although largely unproven link to antibiotic-resistant infections in humans, and what some consider antibiotic misuse. When government regulation restricts use of antibiotics the negative economic impact is not often considered.

Track 5: Alternative Strategies for antimicrobial resistance worldwide

There is a renewed interest in the antibiotic sector, which is evident from the most recent patents and investments. Bacterial vaccines and new antibiotic classes are gaining a tremendous amount of attention with several product candidates in clinical development. These new products are expected to change the outlook of the antibiotic sector to a large extent over the next 5 years. Several reports focus on anti-infective markets in general. This report, however, focuses exclusively on antibacterials, with a particular emphasis on the emerging problem of antibiotic resistance. It also includes a detailed analysis of the emerging technology trends, which give a clear picture of the future of the sector. This helps to provide regulatory authorities and industry strategists a better perspective on which to base their decisions. BCC Research published a report on this topic in 2002. Since then, the market has witnessed dramatic changes in terms of technology, investment, and regulatory trends, which are captured in this report.  

Track 6: Antimicrobial Resistance: Public Health Concerns

This topic reviews the global antibiotic markets, including discussions on the market development and growth potential over the next 5 years. It also analyses key factors that are driving the market growth. It describes the trends in detail with respect to various antibiotic classes, including the novel classes that are emerging and their technological basis. It includes in-depth discussions of the industry structure and the regulatory environment. It is valuable reading for investors, policymakers, and industry participants. Profiles of leading players in the industry are also included.

Such involved analyses have been conducted to help strategy developers and decision makers within pharmaceutical companies and government bodies. The detailed analyses of the regulatory factors that play major roles in deciding the industry trends are especially useful for legislators involved in government policy development programs. Technology trend and patent analyses give an overview of the new trends with respect to innovation within the sector. 

Track 7: Antibiotic surveillance and safety concerns

In the time since penicillin was discovered nearly 80 years ago, antibiotics have become one of the most important lifesaving weapons in doctors' arsenal against bacterial infection. Now, the Lakeland, Fla.-based Publix grocery store chain is giving away seven of these drugs free of charge to those who have prescriptions for them. Five of these are amoxicillin, ampicillin, cephalexin, erythromycin and penicillin VK -- are commonly used by doctors to treat bacterial infections ranging from ear infections to gonorrhea. But two of the drugs on the list -- ciprofloxacin and sulfamethoxazole/trimethoprim -- are high-grade antibiotics that doctors usually reserve for particularly serious infections.

While some hail the program as a godsend, others fear that the move could lead to overuse of the drugs.

This is because the use of antibiotics comes attached with important considerations. According to the American Academy of Family Physicians, there are certain situations in which antibiotics are helpful -- and many in which they can cause more harm than good.

 PenicillinsCephalosporinsAminoglycosidesGlycopeptidesTetracyclines are antibiotics most commonly showing side effects. 

Track 8: Analytical strategies for Antimicrobials & Antibiotics

The analysis of antibiotic susceptibility disks by high-pressure liquid chromatography (HPLC) methods are presented for the potency determination of mecillinamampicillincarbenicillin, and cephalotjiin alone and in various combinations. Good agreement between HPLC and microbiological data is observed for potency determinations with recoveries of greater than 95%. Relative standard deviations of lower than 2% are recorded for each HPLC method. HPLC methods offer improved accuracy and greater precision when compared to the standard microbiological methods of analysis for susceptibility disks. The most popular analytical methods for the determination of beta-lactams are the chromatographic ones, including high performance liquid-chromatography (HPLC) and thin layer chromatography (TLC).

HPLC offers high sensitivity and separation efficiency, establishing itself as the first choice method for the analysis of beta-lactams; however it is expensive and requires sophisticated equipment. TLC is a less expensive and less complicated chromatographic procedure, which can be successfully used, in the preliminary screening of pharmaceutical substances. In modern analysis, TLC is usually used as a separation method, which establishes the presence or absence of beta-lactam antibiotics above a defined level of concentration.

Track 9: Role of long term antibiotics & antimicrobial in diseases

Antibiotics have been applied for the treatment of autoimmune diseases for over five decades, based on the premise that infections play a role in the initiation and propagation of these entities. The antibiotics market was valued at USD 39.8 million in 2015 and is expected to witness a CAGR of 4.0% over the forecast period. Increasing efforts are being witnessed toward the development of advanced products. According to the data published by the Pew Charitable Trust, in March 2016, about 37 promising molecules were being investigated within the U.S. market. Majority of these, are in phase II clinical trials and are anticipated to hit the market between 2018 - 2020. Furthermore, supportive government legislations, such as the Generating Antibiotics Incentives Now (GAIN) Act are expected to expedite the approval process. GAIN Act has provisions which facilitate development of therapy against antibiotic resistant pathogens.

Market analysis

The worldwide fundamental antibiotics Showcase was esteemed at $39.6 billion of every 2013 and is relied upon to reach $41.2 billion by 2018, at a CAGR of 0.8%. The worldwide market for antifungal therapeutics was esteemed at $10.7 billion in 2013 and is anticipated to reach $12.2 billion in  2018, a five-year compound yearly development rate (CAGR) of 2.7%. This calls for uniting at a forum to discuss the present scenario, uptake and consequences associated with antibiotics and related areas of research.

  • Antibiotic usage varies Globally

Antibiotics changed the world. General deals in the present antibiotics and new products advertise were about $40 billion in 2010. It expanded to $41.5 billion in 2013. By 2019, it is anticipated to increase to $67.5 billion, for a 5-year compound annual growth rate (CAGR) of over 9.6%. The biggest section antibiotic drugs showcase was about $38 billion in 2014; this further expanded to $37 billion in 2016, this anticipated to reach $53 billion in 2017, for a 5-year CAGR of 5.9%. Deals in the bacterial vaccines advertise added up to $3.6 billion in 2010 which expanded slightly to $4.5 billion in 2012. This is anticipated to increase to $15 billion of in 2018, for a 5-year CAGR of 31.6%.

The antibiotics market generated sales of US$42 billion in 2009 all inclusive, representing 46% of sales of anti-infective agents (which additionally incorporate antiviral medications and vaccines) and 5% of the worldwide Pharmaceutical Market. However, the antibiotics market is maturing; it demonstrated a normal yearly development of 4% in the course of recent years, contrasted and a development of 16.7% and of 16.4% for antiviral medications and vaccines, individually.

  • Commonly used antibiotics with their increased percentage of resistance

The worldwide foundational antibiotics market was esteemed at $39.6 billion in 2013 and is relied upon to reach $41.2 billion by 2018, at a CAGR of 0.8%. Since, 2005 this market apparently grows at a yearly rate of 6.6% until 2011. There are many organizations manufacturing antibiotics nowadays and there are numerous different antibiotics present in the market, for example, aminoglycoside antibiotics and it covers around 79% of the worldwide demand. In addition, alternate antibiotics, for example, pencillin have 8%, tetracyclines 4%, erythromycin 7%, streptomycin 1% and chloramnphenicol has 1 % market.

  • Antibiotic market

Organizations working on Antibiotics around the Globe:

  • Infectious Diseases Society of America
  • World Health Organization
  • U.S. Food and Drug Administration (FDA)
  • Center for a Livable Future (CLF)
  • Centers for Disease Control and Prevention (CDC)
  • American Medical Association
  • Animal Welfare Approved (AWA)
  • Center for Food Safety
  • Center for Science in the Public Interest (CSPI)
  • Food Animal Concern Trust (FACT)
  • The Humane Society of the United States (HSUS)
  • The Pew Charitable Trusts
  • Food and Water Watch
  • Healthy Food Action
  • Keep Antibiotics Working (KAW)
  • Natural Resources Defense Council (NRDC)
  • American Nurses Association
  • American Public Health Association
  • Institute of Medicine, National Academies of Science
  • American Society for Microbiology  

 

 

 

 

 

Past Conferences

We gratefully thank all our wonderful Keynote Speakers, Speakers, Delegates, Students, Organizing Committee Members,  Media Partners for making our Past Antibiotics Reistance Conferences (during 2018 in USA Region) the best ever!

   4th International Conference on Antimicrobials, Multiple Drug Resistance & Antibiotics Resistance, April 20-21, 2018

  • Venue: Hilton Garden Inn Las Vegas Strip South 7830 S Las Vegas Blvd, Las Vegas, NV 89123, USA

 

Keynote Speakers

Past Conferences Keynote Speakers

We thank all our Honourable Keynote Speakers for their valuable presence, namely

 

Chairs/Co-Chairs

Past Conferences Chairs/Co-Chairs

We extend our appreciation towards our Chairs and Co-Chairs of the sessions, namely

  • Hideko Kaji, Thomas Jefferson University, USA
  • Akira Kaji, University of Pennsylvania, USA
  • Tore Midtvedt, Karolinska Institute, Sweden and more…

 

Moderators

Past Conferences Moderators

Conference series LLC Ltd expresses its gratitude to the conferences Moderators, for taking up the responsibility to coordinate during the sessions, we are indebted to your support, namely

  • Nataliya Roth, University of Natural Resources and Life Sciences, Austria
  • Helieh S Oz, UK Medical Center, USA and more…

 

Past Conference Report

Antibiotics Resistance 2018

Conference Series LLC Ltd hosted the “4th International Conference on Antimicrobials, Multiple Drug Resistance & Antibiotics Resistance (Antibiotics Resistance 2018) during April 20-21, 2018, 2017 at Hilton Garden Inn Las Vegas Strip South 7830 S Las Vegas Blvd, Las Vegas, NV 89123, USA.

Antibiotics Resistance 2018 is specifically premeditated with a unifying axiom providing platform to widen the imminent scientific discoveries in the field of Antibiotics and Antibiotic Resistance and to deliver novel ideas besides incorporating better understanding of their role in Pharma, Drug Manufacturers, Business Management and Marketing. The scientific meeting has laid the path for the development and the validation of Antibiotics and Antibiotic Resistance under the theme of Advances in Infectious Diseases and future trends in antimicrobials”.

The conference invited Scientific Professionals, Researchers and Corporate Leaders from diverse disciplines emphasizing the areas of types & approaches for Antibiotic Treatment, The Emergence of Antimicrobial Resistance, Antibiotic Resistance: Opportunities and Challenges, Antibiotics for Emerging and Re-emerging Diseases, Antibiotic Prophylaxis etc.

Conference Series LLC Ltd is prerogative to thank the Organizing Committee, Editorial Board Members and Moderator – Dr. Nataliya Roth, University of Natural Resources and Life Sciences, Austria, speaker participants, poster presenters and attendees for enormous support and participation in this grand venture.

The highlights of the meeting were the eponymous lectures, delivered by the following speakers:

Helieh S. Oz, American Association of Gastroenterology, USA

Tore Midtvedt, Karolinska Institute, Sweden

Nataliya Roth, University of Natural Resources and Life Sciences, Austria

Akira Kaji, University of Pennsylvania, USA

Rongshi Li, University of Nebraska Medical Center, USA

John J S Cadwell, FiberCell Systems Inc., USA

Hideko Kaji, Thomas Jefferson University, USA

By the endless support of the Journal of Antivirals & Antiretrovirals & Journal of Medical Toxicology Research & Archives of Medical Biotechnology. Conference Series LLC Ltd is pleased to announce our 5th International Conference on Antimicrobials and Antibiotics Resistance March 22-23, 2019 at Chicago, USA

 


Past Reports  Gallery  

Antibiotics 2017

Conference Series LLC Ltd hosted the “3rd World Congress and Exhibition on Antibiotics and Antibiotic Resistance” (Antibiotics 2017) during July 31-August 01, 2017 at Hilton Garden Inn Milan North, Milan, Italy.

Antibiotics 2017 is specifically premeditated with a unifying axiom providing platform to widen the imminent scientific discoveries in the field of Antibiotics and Antibiotic Resistance and to deliver novel ideas besides incorporating better understanding of their role in Pharma, Drug Manufacturers, Business Management and Marketing. The scientific meeting has laid the path for the development and the validation of Antibiotics and Antibiotic Resistance under the theme of “The Future of Antibiotics: Key Opportunities & Emerging Therapies”.

The conference invited Scientific Professionals, Researchers and Corporate Leaders from diverse disciplines emphasizing the areas of types & approaches for Antibiotic Treatment, The Emergence of Antimicrobial Resistance, Antibiotic Resistance: Opportunities and Challenges, Antibiotics for Emerging and Re-emerging Diseases, Antibiotic Prophylaxis etc.

Conference Series LLC Ltd is prerogative to thank the Organizing Committee, Editorial Board Members and Moderator – Dr. Siham M.Mahgoub, Alzahra Hospital Dubai, UAE, speaker participants, poster presenters and attendees for enormous support and participation in this grand venture.

The highlights of the meeting were the eponymous lectures, delivered by the following speakers:

Byungse Suh, Temple University School of Medicine, USA

Hartmut Derendorf, University of Florida, USA

Surbhi Malhotra Kumar, University of Antwerp, Belgium

Tadashi Shimamoto, Hiroshima University, Japan

Samir Kumar-Singh, University of Antwerp, Belgium

Siham M.Mahgoub, Alzahra Hospital Dubai

By the endless support of the Journal of Drug Metabolism & Toxicology, Advances in Pharmacoepidemiology & Drug Safety, Drug Designing: Open Access and Advances in Antibiotics & Antibodies. Conference Series LLC Ltd is pleased to announce our 4th International Conference on Antimicrobials, Multiple Drug Resistance & Antibiotics Resistance April 20-21, 2018 Las Vegas, USA

 

 


Past Reports  Gallery  

To Collaborate Scientific Professionals around the World

Conference Date May 30-31, 2019

For Sponsors & Exhibitors

[email protected]

Speaker Opportunity

Past Conference Report

Supported By

Journal of Antivirals & Antiretrovirals

Journal of Pharmacovigilance

Journal of Bioequivalence & Bioavailability

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by